Feasibility of Allogeneic Hematopoietic Stem Cell Transplantation for Autoimmune Disease: Position Statement from a National Institute of Allergy and Infectious Diseases and National Cancer Institute–Sponsored International Workshop, Bethesda, MD, March 12 and 13, 2005  by Griffith, Linda M. et al.
F
C
P
A
I
B
I
w
L
T
p
N
G
Biology of Blood and Marrow Transplantation 11:862-870 (2005)
 2005 American Society for Blood and Marrow Transplantation
1083-8791/05/1111-0003$30.00/0
doi:10.1016/j.bbmt.2005.07.009
8easibility of Allogeneic Hematopoietic Stem
ell Transplantation for Autoimmune Disease:
osition Statement from a National Institute of
llergy and Infectious Diseases and National Cancer
nstitute–Sponsored International Workshop,
ethesda, MD, March 12 and 13, 2005
Linda M. Grifﬁth,1 Steven Z. Pavletic,2 Alan Tyndall,3 Christopher N. Bredeson,4 James D. Bowen,5
Richard W. Childs,6 Alois Gratwohl,7 Jacob M. van Laar,8 Maureen D. Mayes,9 Roland Martin,10
Peter A. McSweeney,11 Paolo A. Muraro,10 Harry Openshaw,12 Riccardo Saccardi,13
Brenda M. Sandmaier,14 Stephen J. Forman,15 Richard A. Nash,14 on behalf of the workshop participants
1Division of Allergy, Immunology and Transplantation, National Institute of Allergy and Infectious Diseases,
National Institutes of Health, Bethesda, Maryland; 2Experimental Transplantation and Immunology Branch,
National Cancer Institute, National Institutes of Health, Bethesda, Maryland; 3Department of Rheumatology,
Felix-Platter Spital, Basel, Switzerland; 4Center for International Blood and Marrow Transplantation Research,
Medical College of Wisconsin, Milwaukee, Wisconsin; 5Department of Neurology, University of Washington,
Seattle, Washington; 6Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of
Health, Bethesda, Maryland; 7Departments of Hematology and Internal Medicine, University of Basel,
Kantonsspital, Basel, Switzerland; 8Department of Rheumatology, Leiden University Medical Center, Leiden, The
Netherlands; 9Division of Rheumatology, Department of Medicine, University of Texas-Houston Health Science
Center, Houston, Texas; 10Neuroimmunology Branch, National Institute of Neurological Disorders and Stroke,
National Institutes of Health, Bethesda, Maryland; 11Blood and Marrow Transplant Program, Presbyterian/St.
Luke’s Medical Center, Rocky Mountain Cancer Center, Denver, Colorado; 12Department of Neurology, City of
Hope National Medical Center, Duarte, California; 13Bone Marrow Transplant Unit, UO Ematologia, Policlinico
Careggi, Florence, Italy; 14Clinical Research Division, Fred Hutchinson Cancer Research Center, and University of
Washington, Seattle, Washington; 15Division of Hematology and Hematopoietic Cell Transplantation, City of
Hope National Medical Center, Duarte, California
Correspondence and reprint requests: Steven Z. Pavletic, MD, Experimental Transplantation and Immunology
Branch, National Cancer Institute, WG Magnuson Clinical Center, 10 Center Dr., CRC/Room 4-3130, Bethesda,
MD 20892-1203 (e-mail: pavletis@mail.nih.gov).
Received July 13, 2005; accepted July 14, 2005
KEY WORDS
Allogeneic hematopoietic cell transplantation ● Autoimmune disease ● Clinical trial
c
p
t
t
p
N
c
t
dNTRODUCTION
The primary objective of this 1.5-day workshop
as to critically explore and identify the rationale for
.M.G, S.Z.P., and R.A.N. contributed equally to this work.
he opinions expressed are those of the authors and do not represent the
osition of the National Institute of Allergy and Infectious Diseases, the
ational Cancer Institute, the National Institutes of Health, or the UStovernment.
62linical trials of allogeneic hematopoietic cell trans-
lantation (HCT) in autoimmune diseases, with par-
icular emphasis on multiple sclerosis (MS) and sys-
emic sclerosis. Meeting participants were HCT
hysicians and autoimmune disease experts from
orth America and Europe. The focus of these dis-
ussions was to deﬁne diseases and patient populations
hat may beneﬁt from allogeneic HCT, by rethinking
isease pathophysiology and natural history in light of
oday’s allogeneic HCT technology. We evaluated
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Feasibility of Allogeneic HCT for Autoimmune Disease
Bransplantation protocols, each consisting of a trans-
lantation regimen and associated graft-versus-host
isease (GVHD)–prevention regimen, with regard to
he risk-beneﬁt ratio for patients with autoimmune
iseases. Patients appropriate for allogeneic HCT ap-
roaches will be infrequent, and such individuals
hould be enrolled in approved research protocols
onducted by multidisciplinary teams at highly expe-
ienced centers. In this report, we provide general
ecommendations for how such clinical trials should
e pursued in the immediate future.
ATIONALE FOR ALLOGENEIC HEMATOPOIETIC
RANSPLANTATION AS THERAPY FOR
UTOIMMUNE DISEASE
Allogeneic HCT is widely accepted as curative
herapy for several malignant and nonmalignant dis-
ases [1,2]. It eradicates the host lymphohematopoi-
tic system and provides a new and potentially healthy
onor-derived immune system, which may also con-
ey a lesser genetic risk for recurrent autoimmune
isease. The allogeneic graft also exerts an immune-
ediated graft-versus-host effect that is important for
uccessful engraftment and may be responsible for the
oorly understood clinical phenomenon called the
raft-versus-autoimmunity effect. In some cases, allo-
eneic HCT is associated with the establishment of
ixed hematopoietic chimerism, which may modulate
he host immune system sufﬁciently to induce remis-
ion from the autoimmune disease. Animal models of
utoimmune disease [3], extensive experience in pa-
ients with aplastic anemia [4-6], and a series of pub-
ished clinical case reports in patients with systemic
utoimmune disease [7-12] provide evidence that al-
ogeneic HCT may cure patients with autoimmune
isease. Because currently available standard therapies
or patient populations with severe autoimmune dis-
ases are only partly effective and are not curative,
atients are typically exposed to maintenance or rein-
uction therapies that create cumulative toxicities,
osts, and negative effects on quality of life. Studies of
igh-dose immunosuppressive therapy with autolo-
ous HCT have been promising, but safety and re-
ponse durability are still being investigated, and not
ll patients will tolerate the high-dose regimens.
The potential for 1-time delivery of a curative
herapeutic strategy is appealing. The introduction of
ower-intensity nonmyeloablative conditioning regi-
ens and better prevention and treatment of both
VHD and infections have improved the safety pro-
le of allogeneic HCT. These advances have made
nvestigative studies involving patients with life-
hreatening or severely disabling autoimmune diseases
ossible. However, serious concerns remain regarding
he toxicity and mortality of allogeneic HCT, caused p
B&MTrimarily as a consequence of acute and chronic
VHD. Rare cases have been described in which
utoimmune disease recurred after allogeneic matched
ibling transplantation [8,9,13], but more experience is
equired to identify predisposing risk factors and the
echanism(s) of recurrence.
ISEASE CANDIDATES AND PATIENT POPULATIONS
In general, patients selected to receive allogeneic
CT for autoimmune disease should have a high risk
f mortality or severe disability that is unlikely to be
ured by standard therapies, according to well-deﬁned
actors for a poor prognosis. Patients with systemic
clerosis, some patients with rapidly progressive and
evere MS, high-risk systemic lupus erythematosus,
ediatric lupus, severe therapy-refractory rheumatoid
rthritis, severe autoimmune hematologic cytopenias,
rimary Sjögren syndrome with a systemic presenta-
ion, severe therapy-refractory vasculitis, pediatric
till disease, and dermatomyositis-polymyositis were
iscussed as potential candidates for allogeneic HCT.
ome disease specialists expressed concern that detri-
ental graft-versus-host reactions might be triggered
t nontypical sites, such as areas of central nervous
ystem inﬂammation in patients with MS, but this
oncern is hypothetical at this time. A study interven-
ion such as allogeneic HCT should occur before
rreversible severe organ damage occurs. Certain pa-
ient subsets meeting disease-speciﬁc entry criteria,
ut with borderline organ function that would exclude
hem from autologous HCT clinical trials, may be
andidates for studies of lower-intensity nonmyeloa-
lative regimens and allogeneic HCT. Patients who
xperience treatment failure with autologous HCT
or autoimmune disease and have an aggressive relapse
ight be candidates for clinical trials evaluating allo-
eneic HCT after nonmyeloablative conditioning
egimens. Patients with rheumatoid arthritis have an
xcellent record of efﬁcacy and safety after autologous
CT but also have an excessively high rate of post-
ransplantation disease relapse [14]. Although those
ith severe therapy-resistant rheumatoid arthritis may
e candidates, it is difﬁcult to recommend allogeneic
CT as a therapeutic option for most of these pa-
ients because several effective alternative therapies
re available (Table 1).
The upper age limit for allogeneic HCT for au-
oimmune disease is recommended to be 50 to 55
ears, which would encompass the ages for diagnosis
f most autoimmune diseases; however, some partic-
pants suggested that a lower age limit of 45 to 50
ears should be used. The risk of GVHD and other
oxicities of HCT increases with increasing age. In
ddition, a functional thymus, which exists in younger
atients, may be important for immune reconstitution
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8nd ensuing tolerance [15-18], especially in the setting
f mixed chimerism.
Identiﬁcation of clinical, biologic, or genetic
arkers that are relevant to autoimmune disease pro-
esses or progression, that are speciﬁc for disease
ubtypes, or that are predictive of therapeutic re-
ponses would be an asset for clinical studies and the
evelopment of treatment plans. Unfortunately, there
s a marked absence of such biomarkers for autoim-
une diseases [19-21]. Inclusion of clinical and/or
aboratory assessments based on the proposed mech-
nism of action of the therapy being investigated, for
xample, allogeneic HCT, would be one way to obtain
urther information about biomarkers for autoim-
une diseases. The participants agreed that this
hould be an area of future investigation.
RANSPLANTATION REGIMENS
In general, reduced-intensity and nonmyeloabla-
ive conditioning regimens produce less acute toxicity
hile still enabling donor engraftment, compared
able 1. Allogeneic Hematopoietic Cell Transplantation (HCT) for Aut
opulations Discussed at the Workshop
Disease Patient Subset
eneral criteria Aggressive course or subtype of d
prognostic features
Failure of response to convention
Group who failed high-dose imm
therapy (HDIT) and autologou
High genetic load conveying disea
by criteria yet to be developed
ystemic sclerosis (SSc) Patients with poor prognosis who
standard therapy and would no
toxicity associated with HDIT a
HCT
Those at risk for aggressive hear
ultiple sclerosis Highly aggressive, to be defined b
yet to be developed
ystemic lupus
erythematous (SLE)
Those at risk for severe lung/hea
Severe, treatment-resistant proli
nephritis
SLE with severe systemic vasculit
Very young age of onset
Catastrophic antiphospholipid syn
heumatoid arthritis (RA) Severe, therapy-refractory RA
utoimmune cytopenias Autoimmune hemolytic anemia
Evans syndrome
Pure red cell aplasia
NS indicates central nervous system.ith standard myeloablative regimens, and are there- y
64ore preferred for clinical trials of allogeneic HCT for
utoimmune diseases [22]. Different reduced-intensity
nd nonmyeloablative conditioning regimens vary in
heir degree of myelosuppression and immunosup-
ression. As a consequence, transplant-related toxici-
ies can be variable, thus making it difﬁcult to deter-
ine whether there is one preferred transplantation
egimen. The treatment-related mortality (TRM) and
he incidence of graft rejection and severe GVHD
hould be known for the regimens selected. In addi-
ion, these regimens should have accrued substantial
xperience obtained in more than one center to pro-
ide conﬁdence in translation to multiple centers.
here are several nonmyeloablative regimens for
hich experience is sufﬁcient to merit consideration
or patients with autoimmune diseases [23-30]. How-
ver, because most experience with allogeneic HCT
fter nonmyeloablative conditioning is for patients
ho are too debilitated to receive conventional high-
ose conditioning as a result of age and comorbid
onditions, it is difﬁcult to extrapolate transplant-re-
ated mortality risks for this group to the typically
ne Disease: Selected Disease Candidates and Potential Patient
Specific Limitations and Questions
with poor
apy
pressive
ceptibility
Adverse effects and safety of allogeneic HCT in
patients with significant organ dysfunction
(eg, liver and kidney)
Does allogeneic HCT offer mechanistic
advantages over HDIT and autologous HCT?
Will relapses occur because sibling donors
share too much genetic material with the
patients?
failed
ate the
ologous
isease
Problem of calcineurin inhibitors (GVHD
prophylaxis) and renal adverse effects
Will the development of chronic GVHD
exacerbate SSc, especially in the skin?
t criteria Potential for allogeneic reaction at sites of
inflammation in brain or spinal cord
Potential for leukoencephalopathy–induced or
thrombotic microangiopathy–induced CNS
damage by cyclosporine or tacrolimus
disease
lupus
(CAPS)
Less enthusiastic about nephritis because renal
replacement therapy works well
Course of CAPS is frequently very acute, and
time may not be adequate to identify a donor
Possibility for emerging novel agents
Multiplicity of emerging novel agents
Limited experience suggests benefit [58]oimmu
isease
al ther
unosup
s HCT
se sus
have
t toler
nd aut
t/lung d
y stric
rt/CNS
ferative
is
dromeounger population of patients considered for HCT
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Feasibility of Allogeneic HCT for Autoimmune Disease
Bor treatment of autoimmune disease. These risks may
ary depending on the underlying disease, organ func-
ion, and number and type of prior therapies. As more
xperience with nonmyeloablative regimens is ob-
ained, it may be possible to select or adapt a prepar-
tive regimen depending on the particular disease in-
ication and/or any preexisting organ dysfunction.
ith current nonmyeloablative regimens, the esti-
ated risk of TRM for selected patients who are
ounger and have fewer comorbidities and prior ther-
pies is as high as 10% to 15% and may be higher for
lder patients or those with medical comorbidities.
lthough the risk of TRM may prove to be less for
everal novel regimens currently in development,
hese cannot as yet be recommended for patients with
utoimmune disease because there is little conﬁrma-
ory experience in standard indications for HCT.
Similarly, strategies for GVHD prophylaxis vary,
nd no one approach is clearly superior to another.
VHD prophylaxis is generally considered within the
ontext of the particular nonmyeloablative regimen, as
n integral part of the regimen. Options for prophy-
axis of GVHD include combinations of pharmaco-
ogic agents, T-cell depletion during preparation of
he graft, or therapeutic in vivo and in vitro T cell–
epleting antibodies. The risk of acute or chronic
VHD requiring systemic therapy is estimated to be
0% to 50% in the matched related donor setting and
s related to several factors, including the conditioning
egimen, the choice of GVHD prophylaxis, and the
apidity with which full donor T-cell chimerism is
chieved. More aggressive strategies for GVHD pro-
hylaxis typically result in a higher level of overall
mmunosuppression and a net increase in the risk of
pportunistic infections and relapses. Therefore, de-
elopment of more selective strategies for prophylaxis
f GVHD that eliminate high levels of broad indis-
riminate immunosuppression or overlapping toxici-
ies of immunosuppressive drugs would be an impor-
ant research goal.
Although the risk of TRM after allogeneic HCT
ill likely be higher than that after conventional ther-
py, the initial patients selected for these clinical trials
ill be those with a poor long-term prognosis, many
f whom have disease that is resistant or refractory to
tandard treatments. Most patients meeting entry cri-
eria will have failing internal organ function, poor
uality of life, and signiﬁcant disease-related morbid-
ty and mortality, even though this may be delayed
31-34]. On the basis of preclinical data and case
eports, allogeneic HCT is expected to be highly ef-
ective for inducing sustained remissions or “cure” of
utoimmune diseases. Furthermore, 80% of adult pa-
ients who survive 6 to 18 years after HLA-identical
ibling transplantation have rated their quality of life
s good to excellent and only 5% have rated it as poor,
ven though chronic GVHD requiring 1 to 2 years of d
B&MTmmunosuppressive therapy developed after 33% of
uch transplantations [35]. For patients with aplastic
nemia, the risk of death by the sixth year after allo-
eneic HCT is the same as that of an age- and sex-
atched normal population [36]. Because of the po-
ential for “cure” of disease, some patients may prefer
llogeneic transplantation over standard care, even
ith the current rates of morbidity and mortality
37,38]. Limitations caused by advanced autoimmune
isease, as well as the economic implications of
hronic disability, may be important to patients, even
hough they are difﬁcult to quantify [39]. Therefore,
n a risk-beneﬁt analysis of treatments for autoim-
une diseases, it may be appropriate to consider dis-
ase-related outcomes that include the severity of the
isability, poor quality of life, and expected mortality,
ven though this may be delayed by 10 to 15 years.
TEM CELL SOURCE
After nonmyeloablative conditioning, most trans-
lantation strategies use hematopoietic stem cells col-
ected from peripheral blood (peripheral blood progen-
tor cells; PBPCs). Grafts collected from peripheral
lood after mobilization with growth factors contain
ubstantial CD34 and T-cell doses that minimize the
isk of graft rejection [40]. Review of recent experience
ith unselected PBPCs as compared with bone marrow
rafts for myeloablative allogeneic HCT is strongly sug-
estive, however, that a higher incidence or severity of
hronic GVHD may be associated with PBPC grafts
41-43]. Therefore, bone marrow may be a preferred
tem cell source for patients with autoimmune disease
hen a more intensive preparative regimen is used
23,44]. Research of the optimal stem cell source and
ellular content for hematopoietic cell grafts is therefore
n area of active investigation [45]. Lack of successful
rophylaxis strategies for chronic GVHD is a major
arrier for more successful application of allogeneic
CT in nonmalignant disease.
ONOR SOURCE
The hematopoietic stem cell donor source of
hoice for these initial studies of allogeneic HCT for
utoimmune disease should be an HLA-identical sib-
ing. The potential disadvantages of related donors are
he genetic similarity, which might convey an in-
reased susceptibility for the persistence or recurrence
f the autoimmune disease after allogeneic HCT, and
he limited availability of these donors. Therefore, the
se of matched unrelated donors has certain theoret-
cal advantages, and such donor sources should be
onsidered in future trials after safety and efﬁcacy are
stablished in clinical trials with HLA-identical sibling
onors. Current survival outcomes for traditional ab-
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8ative allogeneic HCT using HLA 10/10 allele–
atched unrelated donors in experienced centers are
ery similar to those after HCT from donors who are
LA-identical siblings [46-48]. The likelihood of
nding a 10/10 allele–matched unrelated donor varies
rom 80% in certain Caucasian patient populations to
s low as 20% in certain ethnic minorities [49,50]. At
his time, for safety reasons, umbilical cord blood or
artially HLA-matched related donors are not recom-
ended for clinical trials of allogeneic HCT in auto-
mmune disease.
RAFT MANIPULATION
CD34-selected grafts have reduced T- and B-cell
oses and are associated with a lower incidence and
everity of GVHD after transplantation [51,52]. In
ddition, manipulated grafts present an opportunity
or future graft engineering research. Disadvantages
f CD34 selection include an increased risk of infec-
ion, a risk of graft rejection (especially after nonmy-
loablative conditioning), and increased cell-process-
ng costs and more complicated logistics. Experience
ith CD34-selected grafts or with other graft ma-
ipulation for allogeneic HCT after nonmyeloablative
onditioning is still limited, however, and in general
hould be pursued only after more experience has
een obtained in patients with other diseases [53].
OLE OF CHIMERISM
Current experience with allogeneic HCT for au-
oimmune disease is insufﬁcient to establish the rela-
ion of mixed (partial donor) or complete (full donor)
himerism to clinical outcomes. The degree of chi-
erism necessary for disease control may vary for
ifferent autoimmune diseases. Theoretical advan-
ages of mixed chimerism include less transplant-re-
ated morbidity (ie, GVHD), more rapid and compre-
ensive immune reconstitution after transplantation,
nd better immune tolerance. Theoretical disadvan-
ages of mixed chimerism include an increased risk of
raft rejection and a higher risk of recurrence of au-
oimmune disease [8,9]. The relative importance of
ineage speciﬁc chimerism—for example, T-cell sub-
ets, B cells, natural killer cells, plasma cells, dendritic
ells, or myeloid lineages—is not yet known [54]. It
ay be important to assess chimerism in situ (eg, in
ymph nodes, thymus, and the central nervous system
r other organs and tissues affected by disease) to
evelop a better understanding of the effect of mixed
himerism on the outcomes of autoimmune disease.
We recommend sequential monitoring of lineage-
peciﬁc chimerism, at a minimum in myeloid, B-cell,
nd T-cell lineages, and, possibly, certain site-speciﬁc
himerism, in future allogeneic HCT protocols for i
66utoimmune diseases. Highly quantitative methods,
or example, analysis of short tandem repeats by poly-
erase chain reaction, are recommended [55,56].
ong-term monitoring beyond 6 months should be
onsidered to assess the persistence of mixed chimer-
sm or the time to full donor chimerism, as well as the
ong-term stability of the graft. To appreciate thera-
eutic mechanisms in allogeneic HCT for autoim-
une disease, it will be important to correlate the
inetics of establishment of donor chimerism with
linical events and other study end points.
For each nonmyeloablative allogeneic HCT regi-
en selected for clinical trials in autoimmune dis-
ases, it will be advantageous to have baseline data
vailable for the kinetics and extent of donor chimer-
sm over time after HCT. This would be an important
eference for clinical management should a patient
xperience recurrent autoimmune disease while a
ixed chimera. For example, if a patient experiences
arly recurrence of autoimmune disease while donor
himerism levels are still increasing, does this repre-
ent a failure of treatment, or will the disease remit as
ull donor chimerism is achieved? We anticipate that
uch questions will also present a challenge for the
esign of clinical trials of allogeneic HCT for auto-
mmune diseases.
ONOR LYMPHOCYTE INFUSIONS
Donor lymphocyte infusions (DLIs), provided ei-
her at predetermined intervals after allogeneic HCT
s part of the transplantation protocol or as immune
herapy after allogeneic HCT in the event of disease
elapse, may be associated with inherent and not al-
ays predictable life-threatening risks—most impor-
antly, GVHD and marrow aplasia. Because treatment
ailure after nonmyeloablative conditioning and allo-
eneic HCT may not necessarily have the same con-
equences for patients with autoimmune diseases as it
ould for patients with malignant diseases, use of DLI
or patients with mixed chimerism and relapse of dis-
ase must be considered carefully. Use of DLI to
ontrol progressive autoimmune disease is unexplored
nd may offer an opportunity for therapeutic beneﬁt
n selected cases in which the risk of poor outcome
fter disease progression exceeds the risk of DLI ad-
inistration [57]. It may be important to determine
ny changes in lineage-speciﬁc chimerism after DLI,
nd their relation to clinical events, in the setting of
linical research protocols. Use of modiﬁed DLI con-
isting of cell subsets or cultured cells with immuno-
odulatory properties, for example, may be an addi-
ional research opportunity when such cellular
roducts are better understood and available for clin-
cal use.
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Feasibility of Allogeneic HCT for Autoimmune Disease
BSSUES IN CLINICAL TRIAL DESIGNS
Research protocols consisting of carefully planned
mall pilot studies of allogeneic HCT as a therapeutic
trategy for severe autoimmune diseases, performed
y dedicated teams of transplantation and disease spe-
ialists, are recommended. Protocols should be well
eveloped and focused on a single disease or subgroup
f a disease, and the patient population should be
learly deﬁned. The goal of such research studies
hould be to explore the safety, efﬁcacy, and biology of
llogeneic HCT for these diseases. Additional consid-
rations and recommendations for the design of clin-
cal trials of allogeneic HCT for autoimmune diseases
re as follows:
1. Cure (durable, immunosuppressive drug free, and
complete remission) of the autoimmune disease is the
goal of allogeneic HCT.
2. Protocols should be developed thoroughly and should
include multiple types of activity assessments, assur-
ances for data collection and analysis, and correlative
immunologic and mechanistic research laboratory
studies.
3. Clinical protocols should preferably be disease speciﬁc,
because the success of a transplantation regimen may
depend on the type of autoimmune disease that is being
treated.
4. The disease status of the patient at baseline (before
transplantation) should be carefully documented, and
baseline characteristics (including age, comorbidities,
and level of organ function) should be speciﬁed. Exten-
sive data on the clinical course before transplantation
should also be available to allow an assessment of the
effect of HCT on disease progression.
5. Eligibility criteria should be precisely deﬁned and re-
producible with regard to disease manifestations, prior
therapies, and the clinical status of each subject at
entry.
6. Patients with advanced autoimmune disease that in-
cludes severe irreversible organ damage should in gen-
eral not be included on such protocols because control of
the autoimmune disease is unlikely to improve disabil-
ity, unless the objective is to prevent further serious
damage (transverse myelitis in systemic lupus erythem-
atosus patients, for example).
7. Tools and instruments that are quantitative, well es-
tablished, and validated should be used whenever pos-
sible to assess primary and secondary end points.
8. Careful attention should be given to the precise deﬁ-
nition of treatment success in the protocol before the
clinical trial is started and should include limited pro-
cedure-related mortality or disability and the require-
ment for continuous disease remission in most patients.
9. Precise goals for the tapering of immunosuppressive
and/or disease-modifying medications that have been
used for the management of the autoimmune disease m
B&MTshould be provided in the protocol at the outset of the
study.
0. A ﬁnal evaluation of the effect of the allogeneic trans-
plantation on autoimmune disease manifestations
should be scheduled after all medications for GVHD
prophylaxis or treatment have been discontinued.
1. Investigations of transplantation biology and disease
mechanisms should be included in the clinical protocols
to advance the understanding of autoimmune disease
processes, responses to therapy, and development of bio-
assays for clinical monitoring.
THER OPEN RESEARCH QUESTIONS
Additional considerations in allogeneic HCT for
utoimmune disease are as follows:
. Patients who have the highest potential to beneﬁt from
allogeneic HCT for autoimmune disease will be early in
their disease course, with a high risk for poor outcome
(including clinical or biologic factors predictive for severe
disease) and a high risk of treatment failure with con-
ventional therapies.
. To optimize the clinical beneﬁt, candidates for clinical
trials of allogeneic HCT should be identiﬁed and re-
ferred for consultation to transplant centers early, before
they have developed irreversible disability as a result of
autoimmune disease.
. Outcomes for allogeneic HCT should be compared with
outcomes for conventional therapy of autoimmune dis-
ease, in appropriately designed clinical trials.
. Mechanisms by which allogeneic HCT, compared with
autologous HCT, may accomplish the control of the
autoimmune disease process within certain target or-
gans, including the central nervous system, should be
described.
. Because control of the autoimmune process may be ex-
pected, the potential of allogeneic stem cells or other cell
therapy to contribute to tissue remodeling should also be
explored.
ONCLUSION/NEXT STEPS
A rationale clearly exists for exploring the thera-
eutic and curative potential of allogeneic HCT for
evere autoimmune disease. Although safer allogeneic
ransplantation strategies have become available, ex-
erience is currently insufﬁcient to allow reliable ex-
rapolation of data on safety and risks from patients
ith malignancies to patients with autoimmune dis-
ases. At present, because of the limited experience
nd variable toxicity and outcome proﬁles associated
ith different conditioning approaches, it is not pos-
ible to deﬁnitively recommend one nonmyeloablative
ransplantation regimen over another. It is recom-
ended that planning be initiated for clinical trials to
867
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8enerate safety and efﬁcacy data for allogeneic HCT
n patients with severe autoimmune diseases. Further
evelopment of novel allogeneic HCT regimens with
ven better safety and toxicity proﬁles is encouraged.
isease and transplantation expert task forces should
e formed to deﬁne patient candidates within each
isease type and the most appropriate transplant reg-
mens. If the initial experience demonstrates adequate
afety and potential efﬁcacy, multicenter controlled
rials will need to be conducted.
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